Published in JAMA on June 08, 1994
Circumvention of outer surface protein A immunity by host-adapted Borrelia burgdorferi. Infect Immun (1995) 2.86
Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect Immun (1998) 2.29
Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc Natl Acad Sci U S A (1997) 1.78
The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis (1999) 1.77
Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease. Infect Immun (1995) 1.68
Biological activities of native and recombinant Borrelia burgdorferi outer surface protein A: dependence on lipid modification. Infect Immun (1994) 1.45
Adaptation of Francisella tularensis to the mammalian environment is governed by cues which can be mimicked in vitro. Infect Immun (2008) 1.25
Molecular analysis of sequence heterogeneity among genes encoding decorin binding proteins A and B of Borrelia burgdorferi sensu lato. Infect Immun (1998) 1.21
Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect Immun (1995) 1.18
The Lyme vaccine: a cautionary tale. Epidemiol Infect (2006) 1.17
Occurrence of severe destructive lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with Borrelia burgdorferi. Infect Immun (2000) 1.08
Detection of anti-Borrelia burgdorferi antibody responses with the borreliacidal antibody test, indirect fluorescent-antibody assay performed by flow cytometry, and western immunoblotting. Clin Diagn Lab Immunol (1996) 0.91
Borrelia burgdorferi escape mutants that survive in the presence of antiserum to the OspA vaccine are killed when complement is also present. Infect Immun (1998) 0.88
Dominant recognition of a Borrelia burgdorferi outer surface protein A peptide by T helper cells in patients with treatment-resistant Lyme arthritis. Infect Immun (1996) 0.86
A role for T cells in the pathogenesis of treatment-resistant Lyme arthritis. Mol Med (1995) 0.83
Inhibition of the production of anti-OspA borreliacidal antibody with T cells from hamsters vaccinated against Borrelia burgdorferi. Infect Immun (1998) 0.81
ELISA-based measurement of antibody responses and PCR-based detection profiles can distinguish between active infection and early clearance of Borrelia burgdorferi. Clin Dev Immunol (2011) 0.79
Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med (1994) 7.61
The mediator of cellular immunity. II. Migration of immunologically committed lymphocytes into inflammatory exudates. J Exp Med (1971) 4.13
The mediator of cellular immunity. I. The life-span and circulation dynamics of the immunologically committed lymphocyte. J Exp Med (1971) 4.00
Interaction of DNA polymerase alpha-primase with cellular replication protein A and SV40 T antigen. EMBO J (1992) 3.53
The mediator of cellular immunity. IV. Cooperation between lymphocytes and mononuclear phagocytes. Cell Immunol (1971) 2.34
An essential Saccharomyces cerevisiae single-stranded DNA binding protein is homologous to the large subunit of human RP-A. EMBO J (1990) 2.28
The mediator of cellular immunity. 3. Lymphocyte traffic from the blood into the inflamed peritoneal cavity. J Exp Med (1971) 2.17
Synergistic impact of measles and diarrhoea on nutrition and mortality in Bangladesh. Bull World Health Organ (1981) 2.06
High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis (1999) 2.02
Relationship between enterotoxin production and serotype in enterotoxigenic Escherichia coli. Infect Immun (1979) 2.01
Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum Pathol (1995) 2.00
Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect Immun (1993) 1.98
Priming and suppression of the intestinal immune response to cholera toxoid/toxin by parenteral toxoid in rats. J Immunol (1980) 1.73
Antibacterial activity of human natural killer cells. J Exp Med (1989) 1.53
The short lived small lymphocyte as a mediator of cellular immunity. Nature (1970) 1.51
Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med (1996) 1.47
Biological activities of native and recombinant Borrelia burgdorferi outer surface protein A: dependence on lipid modification. Infect Immun (1994) 1.45
Comparison of sucrose and glucose in the oral electrolyte therapy of cholera and other severe diarrheas. N Engl J Med (1977) 1.35
Epidemiologic linkage of rodent and human hantavirus genomic sequences in case investigations of hantavirus pulmonary syndrome. J Infect Dis (1996) 1.33
Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther (1999) 1.31
Cellular immunity in Q fever: modulation of responsiveness by a suppressor T cell-monocyte circuit. J Immunol (1985) 1.30
Alterations in lymphocyte cell surface markers during various human infections. Am J Med (1983) 1.27
High levels of viremia in patients with the Hantavirus pulmonary syndrome. J Infect Dis (1999) 1.24
Renal histopathology in the hemolytic-uremic syndrome following shigellosis. Clin Nephrol (1984) 1.24
Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. Virology (1997) 1.21
Vasculitic and encephalitic complications associated with Coccidioides immitis infection of the central nervous system in humans: report of 10 cases and review. Clin Infect Dis (1992) 1.18
Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine (2000) 1.15
Cloning, overexpression, and genomic mapping of the 14-kDa subunit of human replication protein A. J Biol Chem (1993) 1.15
Antibody-dependent cellular cytotoxicity of Coxiella burnetii-infected J774 macrophage target cells. Infect Immun (1984) 1.11
Cellular immunity in Q fever: specific lymphocyte unresponsiveness in Q fever endocarditis. J Infect Dis (1985) 1.10
Nutritional status: a determinant of severity of diarrhea in patients with cholera. J Infect Dis (1976) 1.08
Hantavirus pulmonary syndrome-related virus from Bolivia. Lancet (1996) 1.08
Hantavirus pulmonary syndrome: radiographic findings in 16 patients. Radiology (1994) 1.01
Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J (1997) 0.99
Parenteral immunization causes antigen-specific cell-mediated suppression of an intestinal IgA response. J Immunol (1983) 0.99
Clarithromycin-induced mania in two patients with AIDS. Clin Infect Dis (1995) 0.93
Antibody response to phenolic glycolipid I in inbred mice immunized with Mycobacterium leprae. Infect Immun (1985) 0.93
Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome. Clin Infect Dis (2001) 0.89
Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr (1993) 0.84
Prostaglandins from human T suppressor/cytotoxic cells modulate natural killer antibacterial activity. J Exp Med (1989) 0.84
Cellular immune competence and diarrheal morbidity in malnourished Bangladeshi children: a prospective field study. Am J Clin Nutr (1987) 0.83
Strain variations in the murine cellular immune response to the phenolic glycolipid I antigen of Mycobacterium leprae. Infect Immun (1986) 0.83
Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants. Pediatr Infect Dis J (1997) 0.81
Selective proliferation of natural killer cells among monocyte-depleted peripheral blood mononuclear cells as a result of stimulation with staphylococcal enterotoxin B. Infect Immun (1989) 0.81
Hantavirus pulmonary syndrome in pregnancy. Clin Infect Dis (1999) 0.81
Cellular and humoral immune response to a phenolic glycolipid antigen (PhenGL-I) in patients with leprosy. J Clin Microbiol (1987) 0.80
Effect of pyridoxalated stabilized stroma-free hemoglobin solution on the clearance of intravascular lipid by the reticuloendothelial system. Circ Shock (1985) 0.79
Population distributions of natural killer and K562 target cell conjugates. Nat Immun Cell Growth Regul (1989) 0.78
Aeromonas hydrophila in the coelomic cavity of the earthworms Lumbricus terrestris and Eisenia foetida. J Invertebr Pathol (1977) 0.78
Experimental and theoretical kinetics study of antibacterial killing mediated by human natural killer cells. J Immunol (1989) 0.77
Characterization of a recombinant outer surface protein A (OspA) vaccine against Lyme disease. Dev Biol (Basel) (2000) 0.77
The maximum conjugate frequency (alpha max) characterizes killer cell populations. J Immunol Methods (1989) 0.77
Ascorbate-2-phosphate in red cell preservation. Clinical trials and active components. Transfusion (1988) 0.76
Well-defined cell-surface receptors may be entry points for infectious agents. Scand J Immunol (1986) 0.76
Circulating immune complexes in bacillary and amebic dysentery. J Clin Lab Immunol (1981) 0.76
Removal of bacteria from blood. Mil Med (1987) 0.75
Effect of polymyxin B on hemoglobin-mediated hepatotoxicity. Mil Med (1989) 0.75
Parenteral ciprofloxacin compared with ceftazidime in the treatment of serious upper and lower urinary tract infection. Diagn Microbiol Infect Dis (1990) 0.75
Immunogenicity and reactogenicity of the Biken acellular pertussis vaccine in young adults. Vaccine (2000) 0.75
Chemotactic attraction of Lumbricus terrestris coelomocytes to foreign tissue. Dev Comp Immunol (1979) 0.75
Model for population distributions of lymphocyte-target cell conjugates. J Theor Biol (1989) 0.75
Disseminated macronodular cutaneous candidiasis in chronic alcoholism. Arch Intern Med (1986) 0.75
Deleterious effects of stroma-free hemoglobin used as resuscitative fluid for rats with ischemic intestinal shock. Crit Care Med (1988) 0.75
Stroma-free methemoglobin solution as an antidote for cyanide poisoning: a preliminary study. J Toxicol Clin Toxicol (1984) 0.75
Optimization and synthesis of pyridoxalated polymerized stroma-free hemoglobin solution. Mil Med (1988) 0.75
Electron-microscopic observations of normal coelomocytes from the earthworm, Lumbricus terrestris. Cell Tissue Res (1977) 0.75
Physical evidence for the temporal transition of transcription in bacteriophage lambda. Mol Gen Genet (1982) 0.75
Antibody response to transfusion with pyridoxalated polymerized hemoglobin solution. Mil Med (1987) 0.75
Pyridoxalated polymerized stroma-free hemoglobin solution (SFHS-PP) as an oxygen-carrying fluid replacement for hemorrhagic shock in dogs. Mil Med (1987) 0.75
Efficacy of antibacterial membrane and effect on blood components. Mil Med (1988) 0.75
Pelvic hematoma after intercourse while on chronic anticoagulation. Ann Emerg Med (1984) 0.75
Graft rejection in earthworms: an electron microscopic study. Eur J Immunol (1977) 0.75
Earthworm coelomocytes in vitro. In Vitro (1977) 0.75
Effect of conjugate size on the kinetics of cell-mediated cytotoxicity at the population level. J Theor Biol (1989) 0.75